JP2012533539A5 - - Google Patents

Download PDF

Info

Publication number
JP2012533539A5
JP2012533539A5 JP2012520571A JP2012520571A JP2012533539A5 JP 2012533539 A5 JP2012533539 A5 JP 2012533539A5 JP 2012520571 A JP2012520571 A JP 2012520571A JP 2012520571 A JP2012520571 A JP 2012520571A JP 2012533539 A5 JP2012533539 A5 JP 2012533539A5
Authority
JP
Japan
Prior art keywords
ray diffraction
salt according
salt
proliferative disorder
theta scale
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012520571A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012533539A (ja
JP6013911B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/SG2010/000265 external-priority patent/WO2011008172A1/en
Publication of JP2012533539A publication Critical patent/JP2012533539A/ja
Publication of JP2012533539A5 publication Critical patent/JP2012533539A5/ja
Application granted granted Critical
Publication of JP6013911B2 publication Critical patent/JP6013911B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012520571A 2009-07-15 2010-07-14 9e−15−(2−ピロリジン−1−イル−エトキシ)−7,12,25−トリオキサ−19,21,24−トリアザ−テトラシクロ[18.3.1.1(2,5).1(14,18)]ヘキサコサ−1(24),2,4,9,14,16,18(26),20,22−ノナエンのクエン酸塩 Active JP6013911B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22560909P 2009-07-15 2009-07-15
US61/225,609 2009-07-15
PCT/SG2010/000265 WO2011008172A1 (en) 2009-07-15 2010-07-14 9e-15-(2-pyrrolidin-1-yl-ethoxy)-7,12,25-trioxa-19,21,24-triaza- tetracyclo[18.3.1.1(2,5).1(14)18)]hexacosa-1(24),2,4,9,14,16,18(26),20,22-nonaene citrate salt

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015094972A Division JP2015164941A (ja) 2009-07-15 2015-05-07 9e−15−(2−ピロリジン−1−イル−エトキシ)−7,12,25−トリオキサ−19,21,24−トリアザ−テトラシクロ[18.3.1.1(2,5).1(14,18)]ヘキサコサ−1(24),2,4,9,14,16,18(26),20,22−ノナエンのクエン酸塩

Publications (3)

Publication Number Publication Date
JP2012533539A JP2012533539A (ja) 2012-12-27
JP2012533539A5 true JP2012533539A5 (enExample) 2013-08-29
JP6013911B2 JP6013911B2 (ja) 2016-10-25

Family

ID=42790728

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012520571A Active JP6013911B2 (ja) 2009-07-15 2010-07-14 9e−15−(2−ピロリジン−1−イル−エトキシ)−7,12,25−トリオキサ−19,21,24−トリアザ−テトラシクロ[18.3.1.1(2,5).1(14,18)]ヘキサコサ−1(24),2,4,9,14,16,18(26),20,22−ノナエンのクエン酸塩
JP2015094972A Pending JP2015164941A (ja) 2009-07-15 2015-05-07 9e−15−(2−ピロリジン−1−イル−エトキシ)−7,12,25−トリオキサ−19,21,24−トリアザ−テトラシクロ[18.3.1.1(2,5).1(14,18)]ヘキサコサ−1(24),2,4,9,14,16,18(26),20,22−ノナエンのクエン酸塩

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015094972A Pending JP2015164941A (ja) 2009-07-15 2015-05-07 9e−15−(2−ピロリジン−1−イル−エトキシ)−7,12,25−トリオキサ−19,21,24−トリアザ−テトラシクロ[18.3.1.1(2,5).1(14,18)]ヘキサコサ−1(24),2,4,9,14,16,18(26),20,22−ノナエンのクエン酸塩

Country Status (18)

Country Link
US (1) US9062074B2 (enExample)
EP (1) EP2454266B1 (enExample)
JP (2) JP6013911B2 (enExample)
CN (1) CN102762577B (enExample)
AR (2) AR077483A1 (enExample)
BR (1) BR112012000750B1 (enExample)
CA (1) CA2768210C (enExample)
DK (1) DK2454266T3 (enExample)
ES (1) ES2429525T3 (enExample)
HR (1) HRP20130941T1 (enExample)
MX (1) MX2012000680A (enExample)
PL (1) PL2454266T3 (enExample)
PT (1) PT2454266E (enExample)
RU (1) RU2543721C2 (enExample)
SI (1) SI2454266T1 (enExample)
SM (1) SMT201300112B (enExample)
TW (1) TWI537276B (enExample)
WO (1) WO2011008172A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2966753A1 (en) 2014-11-17 2016-05-26 Arno Therapeutics, Inc. Onapristone extended-release compositions and methods
AU2016326657B2 (en) 2015-09-25 2019-10-24 Context Biopharma, Inc. Methods of making onapristone intermediates
CA3008422A1 (en) 2015-12-15 2017-06-22 Context Biopharma Inc. Amorphous onapristone compositions and methods of making the same
US20180148471A1 (en) 2016-11-30 2018-05-31 Arno Therapeutics, Inc. Methods for onapristone synthesis dehydration and deprotection

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY110603A (en) * 1993-05-27 1998-08-29 Novartis Ag Tetrahydropyran derivatives
US7151096B2 (en) * 2003-03-05 2006-12-19 Irm Llc Cyclic compounds and compositions as protein kinase inhibitors
CN101365703B (zh) * 2005-11-16 2013-11-06 S*Bio私人有限公司 杂烷基连接的嘧啶衍生物

Similar Documents

Publication Publication Date Title
JP2014518266A5 (enExample)
JP2014524442A5 (enExample)
JP2013509429A5 (enExample)
JP2015522037A5 (enExample)
JP2013237682A5 (enExample)
JP2014502638A5 (enExample)
JP2015509536A5 (enExample)
JP2015530389A5 (enExample)
ES2613716T3 (es) Formas cristalinas de un derivado de purina
JP2015145426A5 (enExample)
IL296199B2 (en) Salt form of a human hi stone methyltransf erase ezh2 inhibitor
JP2014527042A5 (enExample)
IL250439A0 (en) Use of fingolimod, or a phosphate derivative thereof or a pharmaceutical acceptable salt thereof for the preparation of a drug for the treatment of multiple sclerosis
JP2012255026A5 (enExample)
JP2013518107A5 (enExample)
IL295418B1 (en) Beta-d-2'-deoxy-2' alpha-fluoro-2'-bata-c-modified-2-different-n6-purine modified nucleotides for the treatment of hepatitis c virus
JP2014503593A5 (enExample)
JP2015500331A5 (enExample)
JP2015193630A5 (enExample)
JP2014505107A5 (enExample)
JP2012519182A5 (enExample)
JP2012512164A5 (enExample)
GEP20166488B (en) Co-crystals and salts of ccr3-inhibitors
RU2012146517A (ru) Соли ральтегравира и их кристаллические формы
JP2015516419A5 (enExample)